PHARMA COLLECTIONS AS
Score · fiscal year 2025
43of 100
How to read this: the company is ahead of 37 % of small companies in the same sector in 2025. What does this mean?
Rank: 19,485 of 30,442 · Handel
Profile
Beaver · Builder
Lower profitability, lower solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 49 and solidity 11 out of 100 among small companies in the same sector in 2025. Methodology
Against the sector
PHARMA COLLECTIONS AS is 7 points below the median for small companies in the same sector in 2025.
Median score 50 among 28,491 companies.
Against small companies in the same sector in 2025: operating margin 1.1% (median 2.2%) and equity ratio 0.2% (median 35.1%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 93 MNOK | 3 MNOK |
| Operating margin | 1.1% | 2.2% |
| Profit margin | 1.1% | 2.0% |
| Return on assets | 5.1% | 3.2% |
| Equity ratio | 0.2% | 35.1% |
| Debt-to-equity | 643.05 | 1.05 |
| Current ratio | 1.05 | 1.64 |
| Revenue growth | 81.9% | 3.8% |
The median and “ahead of” refer to small companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 43, PHARMA COLLECTIONS AS does better than 37% of small companies in the same sector (28,889 companies) in 2025.
Score 2023–2025
- PHARMA COLLECTIONS AS
- Median: small companies in the same sector
PHARMA COLLECTIONS AS has a score of 43 for 2025, rank 19,485 of 30,442 in the sector.
Strongest: Growth: percentile 89 against peers, revenue growth 81.9% against a median of 3.8%.
Weakest: Solidity: percentile 11 against peers, equity ratio 0.2% against a median of 35.1%. Liquidity: percentile 29 against peers, current ratio 1.05 against a median of 1.64.
Worth a closer look
- The equity ratio is very low. Could the company absorb a bad year, and does it need more equity? Based on: equity ratio 0.2% (median 35.1%).
- Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have? Based on: revenue growth 81.9% (median 3.8%); current ratio 1.05 (median 1.64).
- What lies behind weak solidity, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
PHARMA COLLECTIONS AS had an operating margin of 1.1% and an equity ratio of 0.2% in 2025, and ranks 19,485 of 30,442 in Handel.
From 2024 to 2025: the equity ratio fell from 49.7% to 0.2% and revenue grew by 82%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 0 MNOK and 8 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 8 MNOK |
| EV/EBIT | 8.0 | 7 MNOK |
| P/B | 1.0 | 0 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- watch
The equity ratio is very low. Could the company absorb a bad year, and does it need more equity?
Based on: Equity ratio 0.2% (median 35.1%).
- watch
Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have?
Based on: Revenue growth 81.9% (median 3.8%); Current ratio 1.05 (median 1.64).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2017, the sector's weakest year, for this company.
The sector's weakest year was 2017, with a median operating margin of −134.9%. Based on the 10 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 49 | weight 30% |
|---|---|---|
| Solidity | 11 | weight 25% |
| Liquidity | 29 | weight 15% |
| Growth | 89 | weight 15% |
| Consistency | 50 | weight 15% |
Durability: 48 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is PHARMA COLLECTIONS AS?
The operating margin was 1.1% in 2025, against a median of 2.2% among small companies in the same sector. Return on assets was 5.1%.
How solid is PHARMA COLLECTIONS AS?
The equity ratio was 0.2% in 2025 (median 35.1%). Debt-to-equity was 643.05 (median 1.05).
What is the liquidity of PHARMA COLLECTIONS AS like?
The current ratio was 1.05 in 2025 (median 1.64).
How does PHARMA COLLECTIONS AS compare in Handel?
PHARMA COLLECTIONS AS ranks 19,485 of 30,442 in Handel for 2025. Among companies of the same size (small companies) it ranks 18,189 of 28,889. Revenue changed by 81.9% from the year before.
Group accounts
The company is registered as part of a group, but we have no group accounts for it. Group accounts are filed by the parent company, and open data does not say which company that is.
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
We do not show the group structure, because open data does not say who owns whom.
From the Central Coordinating Register
- Org. no.
- 929082729
- Legal form
- AS · part of a group
- Sector
- Handel (46.180)
- Size tier
- small
- Employees
- 0–4 (not registered)
- Founded
- 13 March 2022 4 years in operation
- Share capital
- 0.03 MNOK
- Business address
- Birkedalsveien 80, 4640 SØGNE (KRISTIANSAND)
- Municipality
- Kristiansand rank 2–6 of 11 in KOSTRA group 12
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Trond Gabrielsen
- Chair of the board
- Trond Gabrielsen
- Auditor
- BDO AS
- Accountant
- OPK AS
Source: Central Coordinating Register, fetched 25 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 27 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 40 | 61 | 43 | |
| Rank | 17,416 | 8,082 | 19,485 | |
| Operating margin | −1.1% | 0.2% | 1.1% | |
| Return on assets | −39.2% | 11.4% | 5.1% | |
| Equity ratio | 43.4% | 49.7% | 0.2% | |
| Current ratio | 1.77 | 1.99 | 1.05 | |
| Revenue growth | – | 79.5% | 81.9% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 28.5 MNOK | 51.2 MNOK | 93.1 MNOK |
| Operating profit | −0.3 MNOK | 0.1 MNOK | 1.0 MNOK |
| Profit before tax | −0.3 MNOK | 0.1 MNOK | 1.0 MNOK |
| Net profit | −0.3 MNOK | 0.1 MNOK | 0.8 MNOK |
| Financial expenses | 0.0 MNOK | 0.0 MNOK | 0.0 MNOK |
| Total assets | 0.8 MNOK | 0.9 MNOK | 19.3 MNOK |
| Current assets | 0.8 MNOK | 0.9 MNOK | 19.2 MNOK |
| Equity | 0.4 MNOK | 0.4 MNOK | 0.0 MNOK |
| Retained earnings | 0.1 MNOK | 0.2 MNOK | 0.0 MNOK |
| Total liabilities | 0.5 MNOK | 0.4 MNOK | 19.3 MNOK |
| Current liabilities | 0.5 MNOK | 0.4 MNOK | 18.4 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 27 October 2026, accounts id 6515889.
Further
Similar companies
- MALERBODEN STORD AS index 43, rank 19,483 · compare
- P A DRAGESET AS index 43, rank 19,484 · compare
- HOFFMEISTER AS index 43, rank 19,486 · compare
- ALEXANDER ADRIAANSE AS index 43, rank 19,487 · compare
- KROKSTAD GÅRDSMAT AS index 43, rank 19,488 · compare